NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS
Post# of 97
Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering novel therapies for neurodegenerative diseases. Recent clinical trials of the company’s lead compound yielded encouraging results, with buntanetap shown to improve cognition in both Alzheimer’s and Parkinson’s patients. The company also introduced a new crystalline form of buntanetap with improved properties, “offering significant advantages over the less structured, old semi-crystalline form,” according to a recent article.
“Annovis filed the new crystalline form with the International Patent Cooperation Treaty and a provisional patent for the manufacturing of this crystalline form, covering the entire synthesis process. The company also received approval from the Food and Drug Administration to continue the clinical development with this new form of buntanetap. Additionally, the company was granted a U.S. patent for the use of buntanetap in the treatment of acute traumatic brain injury, expanding its coverage, since acute indication claims had been previously granted in Europe and worldwide,” the article reads. “These milestones position us strongly as we move closer to providing much-needed treatments to patients,” said Annovis Bio Founder, President and CEO Maria L. Maccecchini, Ph.D.
For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer